Gerresheimer Faces Legal Scrutiny and Technical Pressure

German pharma packager Gerresheimer battles a 68% stock plunge, a DSW damages probe, SDAX expulsion, and delayed financials as it seeks creditor talks.

The German pharmaceutical packaging supplier Gerresheimer is navigating a perfect storm of legal, operational, and technical pressures. While its shares showed a slight uptick of about one percent to EUR 17.44 on Tuesday, this minor gain is overshadowed by a staggering 68 percent decline over the past twelve months. The move is seen by market observers as a technical bounce from oversold conditions rather than a sign of fundamental recovery.

Adding a new layer of complexity, shareholder advocacy group Deutsche Schutzvereinigung für Wertpapierbesitz (DSW) is now examining concrete claims for damages against former members of Gerresheimer's executive board. The probe centers on potential breaches of duty related to controversial "bill-and-hold" accounting practices, where revenue may have been booked before goods left the warehouse. This legal action significantly intensifies the company's ongoing crisis.

The fallout from its accounting issues is extensive. Germany's financial regulator, BaFin, has broadened its investigation beyond the revenue bookings. It is now also scrutinizing leasing liabilities, asset impairments in the triple-digit million-euro range within the Advanced Technologies segment, and risks associated with the Bormioli Pharma acquisition. Consequently, the company failed to submit its audited financial statements for 2024/25 on time, triggering its removal from the SDAX index on April 10.

This index expulsion compounds Gerresheimer's challenges. The mandatory selling by ETFs and index funds tracking the SDAX has created structural selling pressure, contributing to a weekly loss of over six percent. The stock now trades approximately 41 percent below its 200-day moving average and about eleven percent below its 50-day average. Its 52-week low of EUR 15.57 remains uncomfortably close, with analysts noting that a sustained break above the EUR 18 mark would be the first concrete signal of the downtrend losing momentum.

Operationally, management is taking steps to shore up the business. The company plans to close its Chicago glass plant by the end of 2026, shifting production to Italy and India. This move is expected to result in non-cash impairments of up to EUR 240 million in the current fiscal year but is aimed at stabilizing margins long-term. Meanwhile, the immediate financial runway is precarious. Executives are currently in talks with creditors to secure extensions and adjustments to financial covenants to avoid a breach.

The timeline for clarity remains extended. The audited annual report is not expected until June 2026 at the earliest, with the Q1 2026 figures and the originally scheduled Annual General Meeting also postponed. This leaves institutional investors without a fundamental basis for reassessment for at least another two months. In this vacuum, speculative elements are gaining influence. Short sellers remain active, with new positions reported on April 12 and 14, contributing to an annualized 30-day volatility near 99 percent. Market chatter also persists about a potential takeover by US competitor Silgan, whose quarterly report due on April 29 is being watched for any indirect clues, though no official confirmation exists.

For Gerresheimer, the path forward involves simultaneously managing creditor negotiations, a prolonged regulatory and legal review, and intense technical market pressures, all while operating without key financial disclosures.